RIGANTI, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 19.031
EU - Europa 11.834
AS - Asia 8.856
AF - Africa 230
SA - Sud America 213
OC - Oceania 123
Continente sconosciuto - Info sul continente non disponibili 40
Totale 40.327
Nazione #
US - Stati Uniti d'America 18.648
CN - Cina 4.921
IT - Italia 3.668
SG - Singapore 1.518
SE - Svezia 1.254
IE - Irlanda 1.179
DE - Germania 1.035
FR - Francia 729
UA - Ucraina 637
AT - Austria 617
DK - Danimarca 586
FI - Finlandia 488
GB - Regno Unito 406
JP - Giappone 346
IN - India 324
HK - Hong Kong 303
VN - Vietnam 293
KR - Corea 289
PL - Polonia 283
CA - Canada 255
ID - Indonesia 251
TW - Taiwan 152
NL - Olanda 133
RU - Federazione Russa 131
ES - Italia 129
MX - Messico 125
TR - Turchia 124
BE - Belgio 117
AU - Australia 106
BR - Brasile 104
SN - Senegal 97
CH - Svizzera 90
IR - Iran 70
PT - Portogallo 70
CZ - Repubblica Ceca 61
GR - Grecia 51
EG - Egitto 44
RO - Romania 42
TH - Thailandia 42
MY - Malesia 37
EU - Europa 35
AR - Argentina 34
CO - Colombia 33
UZ - Uzbekistan 28
HU - Ungheria 24
NO - Norvegia 22
ZA - Sudafrica 22
CL - Cile 21
PH - Filippine 21
SA - Arabia Saudita 21
BY - Bielorussia 20
NZ - Nuova Zelanda 17
NG - Nigeria 16
PK - Pakistan 16
IL - Israele 15
MO - Macao, regione amministrativa speciale della Cina 15
PE - Perù 14
AE - Emirati Arabi Uniti 13
DZ - Algeria 13
JO - Giordania 12
RS - Serbia 10
BG - Bulgaria 9
IQ - Iraq 8
LU - Lussemburgo 8
MU - Mauritius 8
TN - Tunisia 8
AM - Armenia 7
BD - Bangladesh 7
LB - Libano 7
SI - Slovenia 7
CI - Costa d'Avorio 6
LT - Lituania 6
MA - Marocco 6
HR - Croazia 5
SK - Slovacchia (Repubblica Slovacca) 5
BA - Bosnia-Erzegovina 3
EC - Ecuador 3
KE - Kenya 3
KW - Kuwait 3
SD - Sudan 3
UY - Uruguay 3
AF - Afghanistan, Repubblica islamica di 2
AP - ???statistics.table.value.countryCode.AP??? 2
BQ - ???statistics.table.value.countryCode.BQ??? 2
CY - Cipro 2
EE - Estonia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MD - Moldavia 2
MT - Malta 2
SC - Seychelles 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BZ - Belize 1
CR - Costa Rica 1
GF - Guiana Francese 1
IS - Islanda 1
LV - Lettonia 1
Totale 40.321
Città #
Chandler 2.000
Beijing 1.413
Ann Arbor 1.284
Fairfield 1.240
Dublin 1.169
Singapore 1.168
Santa Clara 1.035
Torino 998
Ashburn 987
Houston 920
Woodbridge 678
Wilmington 619
Vienna 582
Seattle 483
Nyköping 471
Turin 452
Cambridge 449
Dearborn 438
Guangzhou 359
Redwood City 353
Jacksonville 337
Medford 331
Columbus 325
Villeurbanne 324
Shanghai 317
Princeton 312
Pisa 289
Jakarta 227
New York 209
Warsaw 206
Nanjing 190
Milan 178
Hangzhou 166
Fremont 165
Dong Ket 158
Frankfurt am Main 149
Boston 125
San Diego 120
Wuhan 108
Boardman 104
Helsinki 99
San Mateo 97
Toronto 97
Taipei 94
Chengdu 90
Tokyo 90
Rome 88
Munich 83
Xian 81
Los Angeles 80
Brussels 78
Shenyang 75
Washington 75
Changsha 72
Jinan 72
Central 71
Hong Kong 71
Hefei 66
London 66
Norwalk 60
Zhengzhou 56
Seoul 55
Lappeenranta 53
Tianjin 47
Kunming 46
Istanbul 45
Chongqing 44
Paris 44
Phoenix 43
Düsseldorf 42
Fuzhou 41
Mountain View 39
Mumbai 39
Hebei 38
Upper Marlboro 38
Buffalo 37
Changchun 37
Silver Spring 37
Florence 36
Shenzhen 35
Central District 34
Ottawa 34
Pune 34
Guiyang 33
Bari 31
Verona 31
Chennai 29
San Jose 29
Falls Church 28
Xiamen 28
Chicago 27
Harbin 27
Nanchang 27
Novara 27
Berlin 26
Siena 26
Suzhou 25
Piemonte 24
Naples 22
Porto 22
Totale 24.459
Nome #
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets 1.654
From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study 725
Impact of cancer metabolism on therapy resistance – Clinical implications 711
Hypoxia as a driver of resistance to immunotherapy 660
Nanoparticelle lipidiche solide per veicolare farmaci antitumorali oltre la barriera emato-encefalica, in particolare per il trattamento dei tumori cerebrali 492
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 470
Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies 458
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 414
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies 405
Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients 362
Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity 359
Treatment with ROS detoxifying gold clusters alleviates the progressive functional decline in a mouse model of Friedreich’s Ataxia 358
Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis. 350
Solid Lipid Nanoparticles for Potential Doxorubicin Delivery in Glioblastoma Treatment: Preliminary In Vitro Studies. 336
Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment 335
Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting 333
Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling. 301
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 299
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 295
A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells. 293
Doxorubicin-Resistant Osteosarcoma: novel therapeutic approaches in sight? 292
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 290
Dealing with indetermination in biochemical networks 287
Cholesterol metabolism: At the cross road between cancer cells and immune environment 283
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 282
Overcoming the Lack of Kinetic Information in Biochemical Reactions Networks 281
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 280
Doxorubicin-antioxidant multitarget drugs 277
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis 277
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 268
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. 267
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 263
Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2a receptor stimulation 263
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins 261
PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy 261
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 256
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 256
ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma 244
What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg 242
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest 232
The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress 228
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells 228
Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R) 222
FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis 218
Antioxidants Prevent the RhoA Inhibition Evoked by Crocidolite Asbestos in Human Mesothelial and Mesothelioma Cells. 209
A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery 209
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 205
Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. 202
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 201
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 201
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1α and P-glycoprotein overexpression 196
Computational modeling of pancreatic cancer cells metabolism 195
Inspecting Energy Releasing Pathways by combination of genomics data and mechanistic approach. 192
Molecular and translational classifications of DAMPs in immunogenic cell death 191
A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis 189
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast 188
Pro- and anti-oxidant properties of near-infrared (NIR) light responsive carbon nanoparticles 184
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells 183
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 182
Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells 182
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells 181
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 180
Inspecting energy releasing pathways by a combination of genomics data and mechanistic approach 179
Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma 173
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: A combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors 168
The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma 167
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 162
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 162
Combination of PDT and NOPDT with a tailored BODIPY derivative 159
Curcumin-loaded solid lipid nanoparticles bypass p-glycoprotein mediated doxorubicin resistance in triple negative breast cancer cells 154
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment. 151
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma 150
The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. 148
Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease 146
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 145
Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells 139
Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells 138
An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo 138
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer 138
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 136
Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells 136
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment 134
Endogenous glutamine decrease is associated with pancreatic cancer progression 133
Applicability and limitations in the characterization of poly-dispersed engineered nanomaterials in cell media by dinamic light scattering (DLS) 133
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug 133
Development of sigma-1 (σ1) receptor fluorescent ligands as versatile tools to study σ1 receptors 132
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 132
Temozolomide down-regulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/GSK3/β-catenin pathway 129
Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae 128
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells 128
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 127
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 125
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 124
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma 124
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells 123
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 123
Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity 123
Mitochondrial metabolic alterations in cancer cells and related therapeutic targets 122
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 120
Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells 119
Totale 24.639
Categoria #
all - tutte 115.356
article - articoli 0
book - libri 0
conference - conferenze 22.520
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.876


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.676 0 0 0 0 0 761 578 478 569 554 400 336
2020/20215.841 389 538 430 350 586 413 548 421 490 497 485 694
2021/20225.989 390 249 292 549 326 319 538 367 306 540 1.252 861
2022/20236.857 615 560 222 639 595 1.519 524 476 739 249 388 331
2023/20245.290 489 660 366 363 378 757 334 390 117 443 457 536
2024/20254.532 255 646 578 874 2.079 100 0 0 0 0 0 0
Totale 41.506